BioMedNewsBreaks

FridayMay 14, 2021 10:54 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is funded and targeting major milestones throughout this year. Corporate highlights for the company included the selection of five clinical sites around the United States for the upcoming phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of PCS499 in treating patients who…

Continue Reading

FridayMay 14, 2021 9:36 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

Continue Reading

ThursdayMay 13, 2021 11:49 am

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Expands Business Development Team

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has welcomed four new members to its business development team, namely Steven Schultz, Warren Thompson, Mitchell Zimmer, and Andrea Ferrari. According to the update, the newly added experts bring extensive experience and expertise in the medical and pharmaceutical industry. The team will focus on expanding RYAH’s presence in multiple verticals within the North America plant-based and nutraceutical markets, including participation in clinical trials for the company’s connected devices and custom software solutions in data analytics. “We are thrilled to announce these new appointments. This team has deep acumen in the medical…

Continue Reading

ThursdayMay 13, 2021 10:26 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Business, Drug-Development Status

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing to a pivotal study stage; the pilot study evaluated the use of the Rotigotine transdermal patch in the treatment for Parkinson's disease. In addition, the update noted that XPhyto had purchased land in Germany for the construction of its commercial drug manufacturing facility in…

Continue Reading

WednesdayMay 12, 2021 12:48 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Poised for Opportunity in Burgeoning Global Health Products Sector

Healthy Extracts (OTCQB: HYEX) is well-positioned to capitalize further on the rapidly growing health products market, which has already positively impacted the company. “The increasing interest, which has led to more demand for the products, has positively impacted HYEX, as evidenced by the company’s improved revenue from $748,377 in 2019 to $1,276,559 in 2020, representing a 71% jump,” reports a recent article. Healthy Extracts wholly owns two subsidiaries — Ultimate Brain Nutrients (“UBN”) and BergaMet North America. The global brain health supplements market, UBN’s domain, “is projected to reach $13.38 billion by 2028, marking a CAGR of 8.0% from 2021…

Continue Reading

TuesdayMay 11, 2021 11:37 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Q2 Virtual Investor Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor Summit at 12:30 p.m. ET on Tuesday, May 18. In addition to the presentation, CNS management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. Interested parties should visit https://ibn.fm/sfnYa for more information and to register for the conference. A video webcast will be accessible on…

Continue Reading

TuesdayMay 11, 2021 11:26 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Announces Sales Team Expansion

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced the hiring of four additional sales representatives, including three for the veterinary market and one for the contract drug manufacturing market. “We are excited to have recruited very talented and experienced sales representatives from some of the biggest names in veterinary health care,” said Dr. Jack Regan, LexaGene’s CEO and founder. “Our new sales representatives have universally expressed optimism about selling LexaGene’s technology into veterinary hospitals, and the same is true for our sales representative targeting contract drug manufacturing organizations.…

Continue Reading

MondayMay 10, 2021 2:21 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Continues Vital Role in Dealing with COVID-19

United Medical Equipment (“UME,” “UMEBSNI”) has, from the beginning of the COVID-19 pandemic, been at the forefront of addressing various emerging needs. “The company acted as a trusted senior referral source for senior care living communities such as independent and assisted living, hospice and memory care,” reads a recent article. “UME also supplied personal protective equipment (‘PPE’) with flexible payment options and provided comprehensive telehealth.” These interventions are in addition to supplying FDA-approved COVID-19 rapid test kits. With the United States being far from reaching herd immunity due to such factors as “varying beliefs around vaccinations throughout the country, the…

Continue Reading

MondayMay 10, 2021 1:35 pm

BioMedNewsBreaks – InnerScope Hearing Technologies Inc. (INND) to Present at Diamond Equity Research Emerging Growth Virtual Conference

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, today announced that its CEO Matthew Moore was invited to present at the Diamond Equity Research Emerging Growth Invitation Virtual Conference. InnerScope will be the only OTC: Pink company invited to present alongside NASDAQ-listed companies for the May 11, 2021, virtual conference. Moore is scheduled to host a virtual presentation to institutional investors at 12:20 p.m. ET, during which he will provide an overview of InnerScope’s business as a disruptive leader in the emerging DTC hearing aid device market, expected to be worth…

Continue Reading

MondayMay 10, 2021 12:22 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth Invitational, the Benzinga Small Cap Conference and the CEO Roadshow Webinar Series. Genprex’s CEO and President Rodney Varner will lead the presentations, which will highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer (“NSCLC”). An archive of the presentations will be available for a period of time following the conferences…

Continue Reading